

U.S.S.N. 10/003,983

Filed: October 31, 2001

AMENDMENT AND RESPONSE TO OFFICE ACTION**Amendment****In the Specification**

Please replace the Abstract on page 45, lines 5-15 with the following Abstract.

A peptide comprising an HLA-binding peptide of human CD45 polypeptide or a portion or variant of said peptide provided that the peptide is not the intact human CD45 polypeptide. Preferably, the peptide comprises the amino acid sequence FLYDVIAST (SEQ ID NO:1) or ALIAFLAFL (SEQ ID NO:2) or KLFTAKLNV (SEQ ID NO:3) or MIWEQKATV (SEQ ID NO:4) or NLSELHPYL (SEQ ID NO:5) or VNLSELHPYL (SEQ ID NO:6) or LLAFGFAFL (SEQ ID NO:7) or YLYNKETKL (SEQ ID NO:8) or LILDVPPGV (SEQ ID NO:9) or TLILDVPPGV (SEQ ID NO:10) or ILYNNHKFT (SEQ ID NO:11) or ILPYDYNRV (SEQ ID NO:12) or YLIHQALV (SEQ ID NO:13) or FQLHDCTQV (SEQ ID NO:14) or KLLAFGFAFL (SEQ ID NO:15) or YQYQYTNWSV (SEQ ID NO:16) or a portion or variant of any of these. Methods of leukaemia immunotherapy using specific cytotoxic T lymphocytes are also disclosed.

Please replace the paragraph spanning pages 15-16 with the following paragraph.

The present invention also relates to a host cell transformed with a polynucleotide vector construct of the present invention. The host cell can be either prokaryotic or eukaryotic. Bacterial cells may be preferred prokaryotic host cells in some circumstances and typically are a strain of *E. coli* such as, for example, the *E. coli* strains DH5 available from Bethesda Research Laboratories Inc., Bethesda, MD, USA, and RR1 available from the American Type Culture Collection (ATCC), of Rockville, MD, USA, 10801 University Boulevard, Manassas, VA 20110-

45061146v1

2

ICY 103
078230/00030

U.S.S.N. 10/003,983

Filed: October 31, 2001

AMENDMENT AND RESPONSE TO OFFICE ACTION

2209 (No ATCC 31343). Preferred eukaryotic host cells include yeast, insect and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human fibroblastic and kidney cell lines. Yeast host cells include YPH499, YPH500 and YPH501 which are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Preferred mammalian host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, monkey kidney-derived COS-1 cells available from the ATCC as CRL 1650 and 293 cells which are human embryonic kidney cells. Preferred insect cells are Sf9 cells which can be transfected with baculovirus expression vectors. Transformation of host cells with DNA and vectors of the invention can be accomplished using methods known in the art.

Please replace the paragraph at page 19, lines 11-16, with the following paragraph.

The human peptide loading deficient cell line T2 is available from the American Type Culture Collection, ~~12301 Parklawn Drive, Rockville, Maryland 20852~~, 10801 University Boulevard, Manassas, VA, 20110-2209 USA under Catalogue No CRL 1992; the *Drosophila* cell line Schneider line 2 is available from the ATCC under Catalogue No CRL 19863; the mouse RMA-S cell line is described in Karre and Ljunggren (1985) *J. Exp. Med.* **162**, 1745, incorporated herein by reference.